Palvella Therapeutics (NASDAQ:PVLA) Shares Up 5.6% – Still a Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price shot up 5.6% on Wednesday . The company traded as high as $113.49 and last traded at $110.55. 16,636 shares changed hands during trading, a decline of 94% from the average session volume of 272,438 shares. The stock had previously closed at $104.67.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PVLA. Mizuho boosted their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. BTIG Research boosted their price objective on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Truist Financial set a $210.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

Palvella Therapeutics Stock Performance

The business’s 50 day simple moving average is $120.93 and its 200-day simple moving average is $107.90. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -27.53 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, sell-side analysts expect that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. KBC Group NV acquired a new position in Palvella Therapeutics during the 1st quarter valued at about $28,000. Group One Trading LLC boosted its stake in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics during the 3rd quarter valued at about $36,000. JPMorgan Chase & Co. lifted its stake in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Palvella Therapeutics in the 2nd quarter worth approximately $85,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.